Macrophage-derived IL-18 targeting for the treatment of Crohn's disease.

Takanori Kanai, Koji Uraushihara, Teruji Totsuka, Akira Okazawa, Toshifumi Hibi, Shigeru Oshima, Tatsuya Miyata, Tetsuya Nakamura, Mamoru Watanabe

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Crohn's disease is an inflammatory bowel disease associated with several changes in the immune system, including an increased number of infiltrating macrophages. These macrophages release a variety of proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-alpha, macrophage infiltrating factor (MIF), interleukin (IL)-6, IL-12 and IL-18, which are critically involved in the onset and the development of Crohn's disease. We here focus on the role of macrophages, especially macrophage-derived IL-18 in both patients with Crohn's disease and a murine model of Crohn's disease.

Original languageEnglish
Pages (from-to)131-136
Number of pages6
JournalCurrent drug targets. Inflammation and allergy
Volume2
Issue number2
DOIs
Publication statusPublished - 2003 Jun
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology

Cite this

Kanai, T., Uraushihara, K., Totsuka, T., Okazawa, A., Hibi, T., Oshima, S., Miyata, T., Nakamura, T., & Watanabe, M. (2003). Macrophage-derived IL-18 targeting for the treatment of Crohn's disease. Current drug targets. Inflammation and allergy, 2(2), 131-136. https://doi.org/10.2174/1568010033484250